BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34298950)

  • 21. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
    Mehta CC; Bhatt HG
    Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
    Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
    J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Roles of AXIN1 and AXIN2 in Tankyrase Inhibitor-Induced Formation of Degradasomes and β-Catenin Degradation.
    Thorvaldsen TE; Pedersen NM; Wenzel EM; Stenmark H
    PLoS One; 2017; 12(1):e0170508. PubMed ID: 28107521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
    Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
    Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
    Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
    Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
    Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS
    Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/
    Yang HY; Shen JX; Wang Y; Liu Y; Shen DY; Quan S
    Biomed Res Int; 2019; 2019():2686340. PubMed ID: 30915350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
    Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H
    Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
    Siraj AK; Kumar Parvathareddy S; Pratheeshkumar P; Padmaja Divya S; Ahmed SO; Melosantos R; Begum R; Concepcion RMJA; Al-Sanea N; Ashari LH; Abduljabbar A; Al-Dayel F; Al-Kuraya KS
    Biomed Pharmacother; 2020 Jan; 121():109572. PubMed ID: 31704613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
    PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of APC-mutant colorectal cancer cells requires interaction between tankyrase and a thiol peroxidase, peroxiredoxin II.
    Kang DH; Lee JHS; Kang SW
    BMB Rep; 2017 Aug; 50(8):391-392. PubMed ID: 28683851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
    Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
    Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
    Mariotti L; Pollock K; Guettler S
    Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.